The 14 Billion Dose COVID-19 Manufacturing Challenge
mRNA Vaccines Leading The Way
Executive Summary
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
You may also be interested in...
Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.